Adenosine A 2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders

European Neurology

Volumn 67, Issue 1, 2012, Pages 4-11

  Kulisevsky, Jaime ^a,b,d   Poyurovsky, Michael ^c  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

Author keywords

Adenosine A 2A receptor antagonism; Basal ganglia; Direct pathway; Dopamine; Drug induced movement disorders; Extrapyramidal symptoms; Indirect pathway; Parkinson's disease; Pharmacological agents

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR; CATALASE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; GLUTATHIONE; HALOPERIDOL; LEVODOPA; SUPEROXIDE DISMUTASE; ADENOSINE A2 RECEPTOR ANTAGONIST;

BRAIN CORTEX; DRUG INDUCED DISEASE; DYSTONIA; GLOBUS PALLIDUS; HUMAN; LIPID PEROXIDATION; MOTOR DYSFUNCTION; NERVE CELL; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; THALAMOCORTICAL TRACT; DYSKINESIA; METABOLISM;

ADENOSINE A2 RECEPTOR ANTAGONISTS; DYSKINESIA, DRUG-INDUCED; HUMANS; PARKINSON DISEASE; RECEPTOR, ADENOSINE A2A;

EID: 82355172005     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000331768     Document Type: Review

References (70)

1. Wu SS, Frucht SJ: Treatment of Parkinson's disease: what's on the horizon? CNS Drugs 2005;19:723-743.
2. Chen JJ: Drug-induced movement disorders. A primer. US Pharm 2007;32: HS16-HS32.
3. Weiden PJ: Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry 2007;68:12-19.
4. Marder SR: Lessons from each drug trial. Am J Psychiatry 2007;164:375-376.
5. Galvan A, Wichmann T: Pathophysiology of parkinsonism. Clin Neurophysiol 2008;119:1459-1474.
6. De Long MR, Wichmann T: Circuits and circuit disorders of the basal ganglia. Arch Neurol 2007;64:20-24.
7. Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA: Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog Neurobiol 2007;83:293-309.
8. Xie X, Ramkumar V, Toth LA: Adenosine and dopamine receptor interactions in striatum and caffeine-induced behavioral activation. Comp Med 2007;57:538-545.
9. Sebastiao AM, Ribeiro JA: Adenosine receptors and the central nervous system. Handb Exper Pharmacol 2009;193:471-534.
10. Ribeiro JA, Sebastiao AM, de Mendonca A: Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol 2002;68:377-392.
11. Naganawa M, Kimura Y, Nariai T, Ishii K, Oda K, Manabe Y, Chihara K, Kiichi I: Formation of binding potential maps of adenosine A1 and A2A receptors using independent component analysis without arterial blood sampling (abstract). J Cerebral Blood Flow Metabol 2005;25:S606.
12. 2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord 2009;15:406-413.
13. Hettinger BD, Lee A, Linden J, Rosin DL: Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 2001;431:331-346.
14. Ferre S: Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology (Berl) 1997;133:107-120.
15. 2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 1991;57:1062-1067.
16. 2A receptors: a new strategy for basal ganglia disorders. Recent Pat CNS Drug Discov 2007;2:1-21.
17. Dayne MR, Larson G, Orona RA, Zahniser NR: Opposing actions of adenosine A2a and dopamine D2 receptor activation on GABA release in the basal ganglia: evidence for an A2a/D2 receptor interaction in globus pallidus. Synapse 1996;22:132-138.
18. Ferre S, Fredholm BB, Morelli M, Popoli P, Fuxe K: Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 1997;20:482-487.
19. Mizuno Y, Hattori N, Kubo S, Sato S, Nishioka K, Hatano T, Tomiyama H, Funayama M, Machida Y, Mochizuki H: Progress in the pathogenesis and genetics of Parkinson's disease. Philos Trans R Soc Lond B Biol Sci 2008;363:2215-2227.
20. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y: Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 1989;163:1450-1455.
21. Hattori N, Tanaka M, Ozawa T, Mizuno Y: Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease. Ann Neurol 1991;30:563-571.
22. Mizuno Y, Matuda S, Yoshino H, Mori H, Hattori N, Ikebe S: An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neurol 1994;35:204-210.
23. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD: Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-389.
24. Sofic E, Lange KW, Jellinger K, Riederer P: Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992;142:128-130.
25. Youdim MB, Ben-Shachar D, Riederer P: Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand Suppl 1989;126:47-54.
26. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez TE, del ST, Munoz DG, de Yebenes JG: The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004;55:164-173.
27. 2A receptors and Parkinson's disease. Handb Exper Pharmacol 2009;193:589-615.
28. Haddad PM, Dursun SM: Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 2008;23(suppl 1): S15-S26.
29. Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E: Acute dystonia during fixeddose neuroleptic treatment. J Clin Psychopharmacol 1990;10:389-396.
30. Crocker AD, Hemsley KM: An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:573-590.
31. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G: Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544.
32. Scharrer J, Tatsch K, Schwarz J, Oertel WH, Konjarczyk M, Albus M: D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiatr Scand 1994;90:266-268.
33. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R: Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry 2005;50:541-547.
34. Harris MK, Shneyder N, Borazanci A, Korniychuk E, Kelley RE, Minagar A: Movement disorders. Med Clin North Am 2009;93:371-388.
35. Poyurovsky M: Acute antipsychotic-induced akathisia revisited. Br J Psychiatry 2010;196:89-91.
36. Gerlach J, Casey DE: Tardive dyskinesia. Acta Psychiatr Scand 1988;77:369-378.
37. Ossowska K: Neuronal basis of neurolepticinduced extrapyramidal side effects. Pol J Pharmacol 2002;54:299-312.
38. Ikeda H, Adachi K, Hasegawa M, Sato M, Hirose N, Koshikawa N, Cools AR: Effects of chronic haloperidol and clozapine on vacuous chewing and dopamine-mediated jaw movements in rats: evaluation of a revised animal model of tardive dyskinesia. J Neural Transm 1999;106:1205-1216.
39. Gunne LM, Haggstrom JE, Sjoquist B: Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 1984;309:347-349.
40. Shirakawa O, Tamminga CA: Basal ganglia GABAA and dopamine D1 binding site correlates of haloperidol-induced oral dyskinesias in rat. Exp Neurol 1994;127:62-69.
41. Thaker GK, Nguyen JA, Tamminga CA: Increased saccadic distractibility in tardive dyskinesia: functional evidence for subcortical GABA dysfunction. Biol Psychiatry 1989;25:49-59.
42. Miller R, Chouinard G: Loss of striatal cholinergic neurons as a basis for tardive and L - dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 1993;34:713-738.
43. Grimm JW, Chapman MA, Zahm DS, See RE: Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats. Synapse 2001;39:51-57.
44. Andreassen OA, Meshul CK, Moore C, Jorgensen HA: Oral dyskinesias and morphological changes in rat striatum during longterm haloperidol administration. Psychopharmacology (Berl) 2001;157:11-19.
45. Burger ME, Fachineto R, Alves A, Callegari L, Rocha JB: Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats. Brain Res 2005;1031:202-210.
46. Meredith GE, Totterdell S, Beales M, Meshul CK: Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. Exp Neurol 2009;219:334-340.
47. Bishnoi M, Chopra K, Kulkarni SK: Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. Eur J Pharmacol 2006;552:55-66.
48. Bishnoi M, Chopra K, Kulkarni SK: Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia. Pharmacol Rep 2007;59:181-191.
49. Varani K, Vincenzi F, Tosi A, Gessi S, Casetta I, Granieri G, Fazio P, Leung E, Maclennan S, Granieri E, Borea PA: A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. FASEB J 2010:587-98.
50. Calon F, Dridi M, Hornykiewicz O, Bedard PJ, Rajput AH, Di Paolo T: Increased adenosine A2 A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 2004;127:1075-1084.
51. 2A receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia. J Neurochem 1995;65:2057-2064.
52. Cunha RA, Ribeiro JA: Purinergic modulation of [(3) H]GABA release from rat hippocampal nerve terminals. Neuropharmacology 2000;39:1156-1167.
53. Trevitt J, Vallance C, Harris A, Goode T: Adenosine antagonists reverse the cataleptic effects of haloperidol: implications for the treatment of Parkinson's disease. Pharmacol Biochem Behav 2009;92:521-527.
54. 2 receptors modulate haloperidolinduced catalepsy in rats. Eur J Pharmacol 1997;328:135-141.
55. Salamone JD, Betz AJ, Ishiwari K, Felsted J, Madson L, Mirante B, Clark K, Font L, Korbey S, Sager TN, Hockemeyer J, Muller CE: Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism. Front Biosci 2008;13:3594-3605.
56. Correa M, Wisniecki A, Betz A, Dobson DR, O'Neill MF, O'Neill MJ, Salamone JD: The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res 2004;148:47-54.
57. 2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2, 4-difluorophenyl]-1- piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1, 5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Ther 2009;330:294-303.
58. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl) 1999;147:90-95.
59. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43:507-513.
60. Wardas J, Konieczny J, Lorenc-Koci E: SCH 58261, an A (2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 2001;41:160-171.
61. 2A antagonist KW 6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide. Neuroscience 2009;163:97-108.
62. 2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure. Psychopharmacology (Berl) 2009;204:103-112.
63. Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K: Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, doubleblind, randomised trial. Lancet Neurol 2011;10:221-229.
64. 2A antagonist theophylline in Parkinson's disease. Clin Neuropharmacol 2002;25:25-31.
65. 2A receptor antagonists on haloperidolinduced movement disorders in primates. Psychopharmacology (Berl) 2008;200:393-401.
66. Weiss B, Santelli S, Lusink G: Movement disorders induced in monkeys by chronic haloperidol treatment. Psychopharmacology (Berl) 1977;53:289-293.
67. Gunne LM, Barany S: Haloperidol-induced tardive dyskinesia in monkeys. Psychopharmacology (Berl) 1976;50:237-240.
68. Kazdoba TM, Bleickhardt CJ, Grzelak ME, Pond AJ, Varty GB, Parker EM, Hunter JC, Hodgson RA: SCH 412348: a selective A2a antagonist, blocks extrapyramidal syndrome induced with typical and atypical antipsychotics in Cebus-apella non human primates (poster). 12th International Congress of Parkinson's Disease and Movement Disorders, Chicago June 2008.
69. 2A receptor antagonists in Parkinson's disease. Pharmacol Ther 2005;105:267-310.
70. Naganawa M, Kimura Y, Nariai T, et al: Formation of binding potential maps of adenosine A1 and A2A receptors using independent component analysis without arterial blood sampling. J Cereb Blood Flow Metab 2005;25:S606.